Ascentage Pharma Group International ADR AAPG
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $20.40
- Day Range
- $18.54–19.25
- 52-Week Range
- $0.00–48.45
- Bid/Ask
- $18.00 / $19.02
- Shares Outstanding
- 93.34M
- Market Cap
- $1.75B
- Volume/Avg
- 12,127 / 11,209
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 20.90
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 767
- Website
- https://www.ascentage.cn
Valuation
|
Metric
|
AAPG
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 9.24 |
Price/Sales | 20.90 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AAPG
|
|---|---|
Quick Ratio | 1.68 |
Current Ratio | 1.79 |
Interest Coverage | −23.38 |
Quick Ratio
AAPG
Profitability
|
Metric
|
AAPG
|
|---|---|
Return on Assets (Normalized) | −37.60% |
Return on Equity (Normalized) | −160.55% |
Return on Invested Capital (Normalized) | −48.43% |
Return on Assets
AAPG
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|VT#KPKp | LOCK|t!@Xl | $123B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|&Tz^<S | LOCK|#LF#Y | $71B | |||
| argenx SE ADR
ARGX
| LOCK|&zYT^Nb | LOCK|Hs | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%SVy$Dh | LOCK|<% | $36B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|qpmBCc? | LOCK|?Ymz | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|f#!?<@>T | LOCK|RR>x | $26B | |||
| Moderna Inc
MRNA
| LOCK|c!$Sz$Y | LOCK|fr | $25B | |||
| Incyte Corp
INCY
| LOCK|W>LN#%# | LOCK|<%L | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|@p$?z&Y | LOCK|nd | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|!$$%@$@ | LOCK|Tk | $16B |
United States